Publications
1. Jorge A. Soto, Diego A. Diaz-Dinamarca, Daniel A. Soto, Magaly J. Barrientos, Flavio Carrion, Alexis Kalergis, Abel Vasquez. Cellular immune response induced by Surface Immunogenic Protein with AbISCO-100 adjuvant vaccination decreases Group B Streptococcus vaginal colonization. Mol Immunol. 2019 Jul;111:198-204. doi: 10.1016/j..
2. Benavente FM, Soto JA, Pizarro-Ortega MS, Bohmwald K, González PA, Bueno SM, Kalergis AM. Contribution of IDO to human respiratory syncytial virus infection. J Leukoc Biol. 2019 May 15. doi: 10.1002/.
3. Acevedo OA, Díaz FE, Beals TE, Benavente FM, Soto JA, Escobar-Vera J, González PA, Kalergis AM. Contribution of Fcγ Receptor-Mediated Immunity to the Pathogenesis Caused by the Human Respiratory Syncytial Virus. Front Cell Infect Microbiol. 2019 Mar 29;9:75. doi: 10.3389/.
4. Jorge A. Soto1, Nicolás M. S. Galvez1, Claudia A. Rivera1, Christian E. Palavecino1, Pablo F. Céspedes1, Emma Rey-Jurado1, Susan M. Bueno1, Alexis M. Kalergis*1,2. Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective cellular and humoral immunity. Front Immunol. 2018 Dec 6;9:2875. doi: 10.3389/.
5. Jorge A Soto, Nicolas M Galvez, Felipe M Benavente, Magdalena S Pizarro-Ortega,Margarita Kam-Lem Lay, Claudia Riedel, Susan M Bueno, Pablo Alberto Gonzalez, Alexis M Kalergis*. Human Metapneumovirus: mechanisms and molecular targets used by the virus to avoid the immune system. Front Immunol. 2018 Oct 24;9:2466. doi: 10.3389/
6. Diaz-Dinamarca DA, Ibañez FJ, Soto DA, Soto JA, Cespedes PF, Muena NA, Garate DS, Kalergis AM, Vasquez AE. Immunization with a Mixture of Nucleoprotein from Human Metapneumovirus and AbISCO-100 Adjuvant Reduces Viral Infection in Mice Model. Viral Immunol. 2018 May;31(4):306-314. doi: 10.1089/. Epub 2018 Jan 26.
7. Díaz-Dinamarca DA1,2, Jerias JI1, Soto DA1, Soto JA1,2, Díaz NV1, Leyton YY1, Villegas RA3, Kalergis AM2,4, Vásquez AE5,6. The Optimisation of the Expression of Recombinant Surface Immunogenic Protein of Group B Streptococcus in Escherichia coli by Response Surface Methodology Improves Humoral Immunity. Mol Biotechnol. 2018 Mar;60(3):215-225. doi: 10.1007/s12033-018-0065-8.
8. Magdalena S. Pizarro-Ortega1 , Angelo T. Castiglione1 , Nicolás MS. Gálvez1, Jorge A. Soto1 , Natalia Muñoz-Durango1 y Alexis M. Kalergis1,2.Current context of the disease caused for VRSh and development of new treatments. Revista del Instituto de Salud Pública de Chile. RISPCH, Volumen N°1, Número N°1, Año 2017.
9. Gálvez NMS1, Soto JA1, Kalergis AM3,4. New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV. Int J Mol Sci. 2017.
10. Rey-jurado E, Soto J, Gálvez N, Kalergis AM. A safe and efficient BCG vectored vaccine to prevent the disease caused by the humanRespiratory Syncytial Virus. Hum Vaccin Immunother. 2017.
11. Andrea E. González, Margarita K. Lay, Evelyn L. Jara, Janyra A. Espinoza, Roberto S. Gómez, Jorge Soto, Claudia A. Rivera, Katia Abarca, Susan M. Bueno, Claudia A. Riedel, Alexis M. Kalergis. Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection. Virulence. 2017.
12. Rubio DP1, Roa LG2, Soto DA1, Velasquez FJ1, Gregorcic NA1, Soto JA3, Martinez MC4, Kalergis AM5, Vasquez AE6. Purification and characterization of saxitoxin from Mytilus chilensis of southern Chile. Toxicon. 2015